Tennis - 26-year-old Argentine tennis player Franco Agamenone has accepted a voluntary provisional suspension under Article 8.3.1(c) of the 2019 Tennis Anti-Doping Programme, according to the ITF website. There will be a full hearing against him pursuant to Article 8 of the Programme.
Agamenone provided a urine sample on 26 March 2019 during his participation at the WTT M15 Pinamar event held in Argentine from 25th to 31st March which was sent to the World Anti Doping Agency (WADA) accredited laboratory in Montreal, Canada.
The sample was found to contain hydrochlorothiazide and metabolite. Hydrochlorothiazide comes under the WADA Prohibited List and hence is also not allowed under the Tennis Integrity Unit programme. On 7 May 2019, Agamenone was charged with an Anti-Doping Rule Violation under Article 2.1 of the Programme (presence of a Prohibited Substance in a Player’s Sample) and accepted a voluntary Provisionally Suspension with effect from 18 July 2019.
Mr Agamenone had (and retains) the right to apply to the Chair of the Independent Tribunal convened to hear her case why the Provisional Suspension should not be imposed but has chosen not to exercise that right to date. Agamenone is currently ranked No.
778 in the ITF World Tennis Rankings and No. 239 in the ATP World Doubles Rankings. He has achieved a career-high ATP singles ranking of No. 377 in September 2017 and a career-high ranking of No. 167 on October 2018. He has won 4 singles titles, including 2 on the ATP Challenger circuit, and 31 doubles titles on the ITF circuit.
In his most recent appearance on the ITF circuit, Agamenone lost in the first round of the Rome event in doubles and in the first round of qualifying for the singles event.